Sep 2026· Human Genetics· Vol 145· 0 citations· 63 references
Medicine
TL;DR
This review outlines four major PRS-informed design strategies: tail sampling based on PRS extremes; discordance sampling based on mismatch between phenotype and PRS-implied risk; conditional and stratified genome-wide association analyses using PRS to adjust for / partition background risk; and residual phenotype analysis of the component of phenotype remaining after the PRS-associated component has been removed.
Abstract
Polygenic risk scores (PRS) quantify the component of disease risk captured by measured additive common variants. Their use as a study design variable, rather than only as a predictive endpoint, broadens their scientific value in human genetics. PRS can define informative extremes of common-variant burden, identify discordance between phenotype and PRS-estimated risk, and facilitate the detection of subgroup-specific or residual mechanisms that may be obscured in conventional case-control analyses. This review outlines four major PRS-informed design strategies: tail sampling based on PRS extremes; discordance sampling based on mismatch between phenotype and PRS-implied risk; conditional and stratified genome-wide association analyses using PRS to adjust for / partition background risk; and residual phenotype analysis of the component of phenotype remaining after the PRS-associated component has been removed. It thus provides a practical framework for sample enrichment, subgroup definition, and calibrated epidemiologic comparison. These designs may be especially informative when integrated with sequencing, multi-omics, longitudinal cohorts, and translationally oriented intervention studies. Their application requires careful attention to data leakage, ancestry-related bias, collider structures, and the limits of interpretation.
BACKGROUND
Polygenic risk score (PRS) has the ability to stratify inherited susceptibility to cancer and, as a complement to monogenic testing, can identify individuals at increased genetic risk even when no pathogenic variant is detected in high- or moderate-penetrance genes. It reflects the combined additive effects...
Adéla Mišove, E. Macháčková, Klára Nováková et al.· Klinicka onkologie· 0 citations
The current state of bench-to-bedside translation of polygenic risk scores (PRS) is reviewed and it is shown that quality standards must be established to ensure that the potential of PRS can be effectively translated into routine clinical practice.
Johannes Schumacher, V. Koch, Carlo Maj et al.· Deutsches Ärzteblatt Interna...· 0 citations
Polygenic risk scores (PRS) assume additive SNP effects, yet genetic risk also arises from interactions between loci and environmental factors that contribute to broad-sense heritability. We developed an extended PRS (ePRS) framework for type 2 diabetes (T2D) that incorporates locus-by-locus non-additive effects beyond...
K. Multerer, P. Atkinson, L. Woods et al.· medRxiv· 0 citations
Polygenic risk scores (PRS) offer considerable potential for precision medicine. How ever, their predictive performance often attenuates when applied to populations that differ from the genome-wide association study (GWAS) training population. There are many potential sources of this portability problem, and one relati...
A. Harikrishnan, C. M. Kelly· medRxiv· 0 citations
Standard polygenic risk scores (PRSs) are constructed based on additive genome-wide association study (GWAS) summary statistics. Nonlinear machine learning methods have been increasingly applied to construct PRSs directly from individual-level data, with the aim of improving predictive performance over standard PRSs th...
J. Zhu, A. Baousi, A. P. Morris et al.· medRxiv· 0 citations
Polygenic risk scores (PRS) have emerged as promising tools for stratifying inherited disease risk, yet their translation into clinical practice is constrained by a critical and frequently unmet requirement: demonstration that scores derived in one cohort retain discriminatory value when applied independently in a diff...
L. Bundalian, A. Velluva, E. Gjermeni et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.